|
US9273283B2
(en)
*
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
|
EP2958943B1
(en)
|
2013-02-20 |
2019-09-11 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
|
US9745368B2
(en)
|
2013-03-15 |
2017-08-29 |
The Trustees Of The University Of Pennsylvania |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
JP6793902B2
(ja)
|
2013-12-20 |
2020-12-02 |
ノバルティス アーゲー |
調節可能キメラ抗原受容体
|
|
ES2963718T3
(es)
|
2014-01-21 |
2024-04-01 |
Novartis Ag |
Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
JP7054622B2
(ja)
|
2014-07-21 |
2022-04-14 |
ノバルティス アーゲー |
ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
|
|
EP3722316A1
(en)
|
2014-07-21 |
2020-10-14 |
Novartis AG |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
ES2791248T3
(es)
|
2014-08-19 |
2020-11-03 |
Novartis Ag |
Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
|
|
US11459390B2
(en)
|
2015-01-16 |
2022-10-04 |
Novartis Ag |
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
JP6961490B2
(ja)
|
2015-04-08 |
2021-11-05 |
ノバルティス アーゲー |
Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
|
|
WO2016168595A1
(en)
|
2015-04-17 |
2016-10-20 |
Barrett David Maxwell |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
US12128069B2
(en)
|
2015-04-23 |
2024-10-29 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
AR105433A1
(es)
|
2015-07-21 |
2017-10-04 |
Novartis Ag |
Métodos para mejorar la eficacia y expansión de las células inmunes
|
|
EP3331913A1
(en)
|
2015-08-07 |
2018-06-13 |
Novartis AG |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
WO2017040930A2
(en)
|
2015-09-03 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Biomarkers predictive of cytokine release syndrome
|
|
HK1257295A1
(zh)
|
2015-12-04 |
2019-10-18 |
Novartis Ag |
用於免疫肿瘤学的组合物和方法
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
WO2018067992A1
(en)
|
2016-10-07 |
2018-04-12 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
|
US11535662B2
(en)
|
2017-01-26 |
2022-12-27 |
Novartis Ag |
CD28 compositions and methods for chimeric antigen receptor therapy
|
|
EP3601561A2
(en)
*
|
2017-03-22 |
2020-02-05 |
Novartis AG |
Compositions and methods for immunooncology
|
|
KR20200086278A
(ko)
|
2017-10-18 |
2020-07-16 |
노파르티스 아게 |
선택적 단백질 분해를 위한 조성물 및 방법
|
|
TWI890660B
(zh)
|
2018-06-13 |
2025-07-21 |
瑞士商諾華公司 |
Bcma 嵌合抗原受體及其用途
|
|
CN109517073A
(zh)
*
|
2018-11-30 |
2019-03-26 |
北京泽勤生物医药有限公司 |
一种靶向治疗肿瘤的融合肽及其应用
|
|
EP3896158A4
(en)
*
|
2018-12-11 |
2022-11-02 |
Kyoto University |
METHODS OF INDUCING A DELETION IN GENOMIC DNA
|
|
US20220160751A1
(en)
*
|
2019-04-02 |
2022-05-26 |
Yale University |
Methods of treatment of diseases and disorders associated with increased tet level, increased h19 level, increased level of tgf signaling, or any combination thereof
|
|
CA3151385A1
(en)
|
2019-05-01 |
2020-11-05 |
Pact Pharma, Inc. |
Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy
|
|
US12344656B2
(en)
|
2019-09-06 |
2025-07-01 |
Crispr Therapeutics Ag |
Genetically engineered T cells having improved persistence in culture
|
|
AR120566A1
(es)
|
2019-11-26 |
2022-02-23 |
Novartis Ag |
Receptores de antígeno quiméricos y sus usos
|
|
BR112022009679A2
(pt)
|
2019-11-26 |
2022-08-09 |
Novartis Ag |
Receptores de antígeno quimérico cd19 e cd22 e usos dos mesmos
|
|
US20230036569A1
(en)
*
|
2019-12-17 |
2023-02-02 |
The General Hospital Corporation |
Engineered immune cells with reduced toxicity and uses thereof
|
|
EP4105232A4
(en)
*
|
2020-02-14 |
2023-10-11 |
Beijing Yongtai Ruike Biotechnology Company Ltd |
Immune cells overexpressing cell signaling regulatory factor introduced from outside and use thereof
|
|
WO2021188836A1
(en)
*
|
2020-03-18 |
2021-09-23 |
Barron Annelise E |
Upregulation of cathelicidin gene expression as an adjuvant to other treatments for diseases
|
|
US12240899B2
(en)
|
2020-06-22 |
2025-03-04 |
Ngm Biopharmaceuticals, Inc. |
LAIR-1-binding agents and methods of use thereof
|
|
TW202227124A
(zh)
|
2020-08-21 |
2022-07-16 |
瑞士商諾華公司 |
用於體內產生ｃａｒ表現細胞的組成物和方法
|
|
EP4501951A3
(en)
*
|
2020-08-25 |
2025-04-30 |
Kite Pharma, Inc. |
T cells with improved functionality
|
|
CN113980134B
(zh)
|
2020-12-11 |
2022-05-31 |
广州百暨基因科技有限公司 |
抗cll1抗体及其应用
|
|
CN113234169B
(zh)
*
|
2020-12-11 |
2022-11-01 |
广州百暨基因科技有限公司 |
靶向cll1嵌合抗原受体及其应用
|
|
US20240325535A1
(en)
*
|
2021-11-11 |
2024-10-03 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods comprising car t cells comprising prdm1 and/or nr4a3 knockout
|
|
KR102521500B1
(ko)
*
|
2021-12-02 |
2023-04-14 |
한국화학연구원 |
증진된 효능을 갖는 면역세포
|
|
CN114350665A
(zh)
*
|
2022-01-19 |
2022-04-15 |
上海优替济生生物医药有限公司 |
IFN-γ抑制剂及其用途
|
|
CN114404592A
(zh)
*
|
2022-02-09 |
2022-04-29 |
复旦大学附属中山医院 |
Tet2作为靶标在治疗缺血性血管疾病中的应用
|
|
WO2024059834A2
(en)
*
|
2022-09-15 |
2024-03-21 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Downregulating inos to increase car-t killing
|
|
WO2025189025A2
(en)
*
|
2024-03-07 |
2025-09-12 |
Biontech Us Inc. |
Methods and compositions for engineering t cells
|